Daniel Mark Blumenthal, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Faculty, Medical | 10 | 2020 | 1204 | 1.890 |
Why?
|
Schools, Medical | 7 | 2020 | 879 | 1.360 |
Why?
|
Career Mobility | 4 | 2020 | 259 | 1.220 |
Why?
|
Medicare Part C | 3 | 2022 | 334 | 1.200 |
Why?
|
Physicians, Women | 7 | 2020 | 509 | 1.170 |
Why?
|
Angina Pectoris | 2 | 2021 | 959 | 1.040 |
Why?
|
Internal Medicine | 4 | 2019 | 1051 | 0.820 |
Why?
|
Reimbursement, Incentive | 3 | 2018 | 543 | 0.800 |
Why?
|
Sex Distribution | 5 | 2019 | 2280 | 0.800 |
Why?
|
Reimbursement Mechanisms | 2 | 2018 | 667 | 0.780 |
Why?
|
Medicare | 14 | 2021 | 6770 | 0.750 |
Why?
|
Mandatory Reporting | 2 | 2018 | 123 | 0.660 |
Why?
|
Hospital Mortality | 8 | 2019 | 5293 | 0.660 |
Why?
|
Coronary Artery Disease | 6 | 2021 | 6403 | 0.660 |
Why?
|
Prescriptions | 1 | 2021 | 386 | 0.630 |
Why?
|
Quality of Health Care | 7 | 2018 | 4331 | 0.630 |
Why?
|
Contract Services | 1 | 2017 | 89 | 0.590 |
Why?
|
Myocardial Infarction | 6 | 2018 | 11461 | 0.590 |
Why?
|
Allergy and Immunology | 1 | 2019 | 176 | 0.580 |
Why?
|
Salaries and Fringe Benefits | 2 | 2017 | 257 | 0.580 |
Why?
|
Biopharmaceutics | 1 | 2016 | 23 | 0.550 |
Why?
|
Hospitals | 5 | 2018 | 3883 | 0.550 |
Why?
|
Health Care Reform | 2 | 2024 | 1247 | 0.540 |
Why?
|
Leadership | 4 | 2020 | 1385 | 0.540 |
Why?
|
United States | 43 | 2024 | 72340 | 0.530 |
Why?
|
Episode of Care | 1 | 2016 | 128 | 0.520 |
Why?
|
Hospitals, Proprietary | 1 | 2015 | 39 | 0.510 |
Why?
|
Prescription Fees | 1 | 2016 | 153 | 0.500 |
Why?
|
Hospitalists | 2 | 2018 | 294 | 0.500 |
Why?
|
Arthroplasty, Replacement | 1 | 2018 | 310 | 0.490 |
Why?
|
Foreign Medical Graduates | 3 | 2021 | 77 | 0.480 |
Why?
|
Certification | 1 | 2017 | 418 | 0.460 |
Why?
|
Hypolipidemic Agents | 1 | 2017 | 609 | 0.420 |
Why?
|
Hospital Costs | 2 | 2024 | 947 | 0.420 |
Why?
|
Ownership | 1 | 2015 | 339 | 0.420 |
Why?
|
Program Development | 3 | 2014 | 1297 | 0.410 |
Why?
|
Postoperative Hemorrhage | 1 | 2016 | 415 | 0.400 |
Why?
|
Drug Costs | 2 | 2017 | 1183 | 0.390 |
Why?
|
Angina, Unstable | 1 | 2016 | 888 | 0.390 |
Why?
|
Interviews as Topic | 1 | 2018 | 2696 | 0.370 |
Why?
|
Patient Readmission | 7 | 2019 | 3271 | 0.370 |
Why?
|
Economics, Hospital | 1 | 2013 | 210 | 0.360 |
Why?
|
Hospitalization | 5 | 2024 | 10721 | 0.360 |
Why?
|
Health Care Costs | 4 | 2024 | 3242 | 0.350 |
Why?
|
Appetite Regulation | 1 | 2010 | 84 | 0.340 |
Why?
|
Sex Factors | 7 | 2020 | 10554 | 0.340 |
Why?
|
Drug-Eluting Stents | 1 | 2016 | 681 | 0.340 |
Why?
|
Nervous System Physiological Phenomena | 1 | 2010 | 115 | 0.340 |
Why?
|
Coronary Artery Bypass | 1 | 2018 | 2188 | 0.320 |
Why?
|
Motivation | 1 | 2018 | 2006 | 0.310 |
Why?
|
Physicians | 7 | 2021 | 4591 | 0.310 |
Why?
|
Critical Care | 2 | 2017 | 2697 | 0.290 |
Why?
|
Curriculum | 3 | 2016 | 3743 | 0.280 |
Why?
|
Colonoscopy | 1 | 2015 | 1394 | 0.270 |
Why?
|
Health Expenditures | 1 | 2018 | 2366 | 0.260 |
Why?
|
Fee-for-Service Plans | 4 | 2019 | 700 | 0.260 |
Why?
|
Delivery of Health Care | 1 | 2024 | 5337 | 0.260 |
Why?
|
Cross-Sectional Studies | 11 | 2021 | 26129 | 0.260 |
Why?
|
Length of Stay | 2 | 2017 | 6426 | 0.260 |
Why?
|
Behavior, Addictive | 1 | 2010 | 462 | 0.240 |
Why?
|
Primary Health Care | 1 | 2021 | 4687 | 0.230 |
Why?
|
Patient Compliance | 1 | 2015 | 2690 | 0.230 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 3889 | 0.230 |
Why?
|
Humans | 57 | 2024 | 761596 | 0.220 |
Why?
|
Coronary Angiography | 1 | 2015 | 4471 | 0.220 |
Why?
|
Quality Improvement | 2 | 2018 | 3802 | 0.220 |
Why?
|
Male | 40 | 2024 | 360846 | 0.220 |
Why?
|
Cardiovascular Diseases | 4 | 2024 | 15502 | 0.210 |
Why?
|
Quality Assurance, Health Care | 4 | 2019 | 2169 | 0.210 |
Why?
|
Female | 40 | 2024 | 392705 | 0.200 |
Why?
|
Education, Medical, Graduate | 1 | 2014 | 2373 | 0.200 |
Why?
|
Electronic Health Records | 3 | 2023 | 4811 | 0.200 |
Why?
|
Clinical Competence | 4 | 2021 | 4793 | 0.200 |
Why?
|
Risk Assessment | 6 | 2018 | 23996 | 0.190 |
Why?
|
Patient Care Team | 1 | 2013 | 2521 | 0.190 |
Why?
|
Subtilisins | 1 | 2021 | 81 | 0.190 |
Why?
|
Aged | 28 | 2024 | 169310 | 0.190 |
Why?
|
Insurance Coverage | 2 | 2022 | 1940 | 0.180 |
Why?
|
Internship and Residency | 3 | 2019 | 5882 | 0.170 |
Why?
|
Medicine | 2 | 2020 | 942 | 0.160 |
Why?
|
Endoribonucleases | 1 | 2021 | 228 | 0.160 |
Why?
|
Cost Control | 1 | 2022 | 628 | 0.160 |
Why?
|
Golf | 1 | 2018 | 16 | 0.160 |
Why?
|
Health Benefit Plans, Employee | 1 | 2022 | 333 | 0.160 |
Why?
|
Health Facility Size | 1 | 2018 | 61 | 0.160 |
Why?
|
Aged, 80 and over | 11 | 2024 | 58984 | 0.160 |
Why?
|
Professional Misconduct | 1 | 2018 | 73 | 0.150 |
Why?
|
Fraud | 1 | 2018 | 66 | 0.150 |
Why?
|
Vinculin | 1 | 2018 | 59 | 0.150 |
Why?
|
Talin | 1 | 2018 | 47 | 0.150 |
Why?
|
Odds Ratio | 3 | 2020 | 9647 | 0.150 |
Why?
|
Feeding Behavior | 1 | 2010 | 3188 | 0.150 |
Why?
|
Immunological Synapses | 1 | 2018 | 59 | 0.150 |
Why?
|
Integrin alpha4beta1 | 1 | 2018 | 119 | 0.150 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5440 | 0.150 |
Why?
|
Gynecology | 1 | 2023 | 526 | 0.150 |
Why?
|
Professional Practice Location | 1 | 2017 | 56 | 0.140 |
Why?
|
Industry | 1 | 2019 | 364 | 0.140 |
Why?
|
Equipment and Supplies | 1 | 2019 | 273 | 0.140 |
Why?
|
Evidence-Based Practice | 2 | 2019 | 495 | 0.140 |
Why?
|
Medicare Part D | 1 | 2021 | 355 | 0.140 |
Why?
|
Age Distribution | 3 | 2018 | 2879 | 0.130 |
Why?
|
Cardiology Service, Hospital | 1 | 2018 | 239 | 0.130 |
Why?
|
Community-Based Participatory Research | 1 | 2018 | 221 | 0.130 |
Why?
|
Middle Aged | 20 | 2024 | 220921 | 0.130 |
Why?
|
Multivariate Analysis | 3 | 2020 | 12059 | 0.130 |
Why?
|
Efficiency | 1 | 2018 | 476 | 0.120 |
Why?
|
Specialization | 2 | 2018 | 778 | 0.120 |
Why?
|
Achievement | 1 | 2016 | 288 | 0.120 |
Why?
|
Secondary Prevention | 1 | 2021 | 1475 | 0.120 |
Why?
|
Acute Coronary Syndrome | 2 | 2018 | 2190 | 0.120 |
Why?
|
Heart Failure | 2 | 2019 | 11671 | 0.120 |
Why?
|
Public Sector | 1 | 2016 | 267 | 0.120 |
Why?
|
Emigration and Immigration | 1 | 2017 | 397 | 0.120 |
Why?
|
Prescription Drugs | 1 | 2021 | 631 | 0.110 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2017 | 495 | 0.110 |
Why?
|
Public Policy | 1 | 2017 | 559 | 0.110 |
Why?
|
Hospitals, Teaching | 1 | 2018 | 1156 | 0.110 |
Why?
|
Congresses as Topic | 1 | 2018 | 803 | 0.110 |
Why?
|
Retrospective Studies | 9 | 2024 | 80647 | 0.100 |
Why?
|
Emergency Medicine | 2 | 2019 | 1198 | 0.100 |
Why?
|
Employee Performance Appraisal | 1 | 2013 | 86 | 0.100 |
Why?
|
Health Facilities | 1 | 2017 | 580 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20568 | 0.100 |
Why?
|
Needs Assessment | 1 | 2018 | 1139 | 0.100 |
Why?
|
Communicable Diseases | 1 | 2020 | 875 | 0.090 |
Why?
|
Adult | 16 | 2024 | 221210 | 0.090 |
Why?
|
Patient Satisfaction | 2 | 2015 | 3462 | 0.090 |
Why?
|
Hyperlipidemias | 1 | 2016 | 771 | 0.090 |
Why?
|
Physician-Patient Relations | 1 | 2024 | 3251 | 0.090 |
Why?
|
Dyspnea | 1 | 2018 | 1347 | 0.090 |
Why?
|
Health Services Research | 4 | 2018 | 1812 | 0.090 |
Why?
|
Surgical Procedures, Operative | 1 | 2021 | 1924 | 0.090 |
Why?
|
Health Personnel | 1 | 2024 | 3335 | 0.090 |
Why?
|
Exercise Test | 1 | 2018 | 2127 | 0.090 |
Why?
|
Angioplasty | 1 | 2012 | 355 | 0.080 |
Why?
|
Patient Care Management | 1 | 2013 | 302 | 0.080 |
Why?
|
Anticholesteremic Agents | 1 | 2016 | 966 | 0.080 |
Why?
|
Logistic Models | 3 | 2020 | 13255 | 0.080 |
Why?
|
Publishing | 1 | 2016 | 833 | 0.080 |
Why?
|
Regression Analysis | 1 | 2018 | 6345 | 0.080 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2018 | 2547 | 0.080 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39106 | 0.080 |
Why?
|
Job Satisfaction | 1 | 2012 | 544 | 0.070 |
Why?
|
Feasibility Studies | 1 | 2018 | 5247 | 0.070 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5485 | 0.070 |
Why?
|
Cholesterol, LDL | 1 | 2016 | 2382 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4878 | 0.070 |
Why?
|
General Surgery | 1 | 2018 | 1692 | 0.070 |
Why?
|
Program Evaluation | 1 | 2014 | 2495 | 0.070 |
Why?
|
Medicaid | 2 | 2019 | 2818 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2018 | 1853 | 0.060 |
Why?
|
Natural Language Processing | 1 | 2015 | 1163 | 0.060 |
Why?
|
Quality of Life | 2 | 2018 | 13367 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2018 | 4369 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5493 | 0.060 |
Why?
|
Postoperative Complications | 2 | 2018 | 15633 | 0.060 |
Why?
|
Home Care Services, Hospital-Based | 1 | 2024 | 45 | 0.060 |
Why?
|
Intensive Care Units | 1 | 2017 | 3744 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2014 | 2759 | 0.060 |
Why?
|
Prevalence | 1 | 2021 | 15733 | 0.060 |
Why?
|
Survival Rate | 1 | 2018 | 12723 | 0.060 |
Why?
|
Drug Industry | 2 | 2021 | 788 | 0.060 |
Why?
|
Metabolic Diseases | 1 | 2010 | 683 | 0.060 |
Why?
|
Radiology | 1 | 2017 | 2113 | 0.050 |
Why?
|
Food | 1 | 2008 | 774 | 0.050 |
Why?
|
Commerce | 1 | 2008 | 607 | 0.050 |
Why?
|
Pennsylvania | 1 | 2024 | 613 | 0.050 |
Why?
|
Models, Theoretical | 1 | 2015 | 3575 | 0.050 |
Why?
|
Food Supply | 1 | 2008 | 544 | 0.050 |
Why?
|
Treatment Outcome | 6 | 2018 | 64685 | 0.050 |
Why?
|
Pilot Projects | 1 | 2014 | 8633 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 3246 | 0.050 |
Why?
|
Prognosis | 2 | 2018 | 29629 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 10212 | 0.040 |
Why?
|
Ribonucleases | 1 | 2021 | 277 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 8002 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9177 | 0.040 |
Why?
|
Depression | 1 | 2018 | 8126 | 0.040 |
Why?
|
Databases, Factual | 3 | 2018 | 7968 | 0.040 |
Why?
|
Paxillin | 1 | 2018 | 86 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7879 | 0.040 |
Why?
|
Cluster Analysis | 1 | 2024 | 2707 | 0.040 |
Why?
|
Community Health Planning | 1 | 2018 | 164 | 0.040 |
Why?
|
Health Services Misuse | 1 | 2018 | 244 | 0.030 |
Why?
|
Cohort Studies | 4 | 2023 | 41495 | 0.030 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 2018 | 377 | 0.030 |
Why?
|
Jurkat Cells | 1 | 2018 | 740 | 0.030 |
Why?
|
Protein Multimerization | 1 | 2021 | 983 | 0.030 |
Why?
|
Lipoproteins, LDL | 1 | 2019 | 642 | 0.030 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2018 | 691 | 0.030 |
Why?
|
Neoplasms | 1 | 2024 | 22173 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2019 | 697 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2018 | 1126 | 0.030 |
Why?
|
Substance-Related Disorders | 1 | 2010 | 4420 | 0.030 |
Why?
|
Tyrosine | 1 | 2018 | 1440 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2019 | 1241 | 0.030 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2018 | 575 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2019 | 1039 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 1516 | 0.020 |
Why?
|
Time Factors | 3 | 2019 | 39969 | 0.020 |
Why?
|
Models, Molecular | 1 | 2021 | 5439 | 0.020 |
Why?
|
Chest Pain | 1 | 2018 | 1091 | 0.020 |
Why?
|
Canada | 1 | 2016 | 2122 | 0.020 |
Why?
|
Age Factors | 2 | 2018 | 18399 | 0.020 |
Why?
|
Internationality | 1 | 2016 | 1001 | 0.020 |
Why?
|
Genetic Testing | 1 | 2023 | 3537 | 0.020 |
Why?
|
Actins | 1 | 2018 | 2050 | 0.020 |
Why?
|
Communication | 1 | 2024 | 3875 | 0.020 |
Why?
|
Stents | 1 | 2021 | 3179 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2021 | 2751 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2020 | 2639 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2016 | 1733 | 0.020 |
Why?
|
Connecticut | 1 | 2008 | 364 | 0.020 |
Why?
|
Cardiology | 1 | 2019 | 1656 | 0.020 |
Why?
|
Incidence | 2 | 2016 | 21355 | 0.020 |
Why?
|
Cell Line | 1 | 2021 | 15601 | 0.020 |
Why?
|
Phosphorylation | 1 | 2018 | 8321 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2017 | 2220 | 0.020 |
Why?
|
Risk | 1 | 2018 | 9610 | 0.020 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2019 | 2242 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3688 | 0.010 |
Why?
|
Education, Medical | 1 | 2016 | 1725 | 0.010 |
Why?
|
Comorbidity | 1 | 2019 | 10508 | 0.010 |
Why?
|
Survival Analysis | 1 | 2016 | 10090 | 0.010 |
Why?
|
Blood Pressure | 1 | 2019 | 8481 | 0.010 |
Why?
|
Vegetables | 1 | 2008 | 1195 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7391 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2018 | 16990 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5841 | 0.010 |
Why?
|
Income | 1 | 2008 | 1877 | 0.010 |
Why?
|
Risk Factors | 2 | 2018 | 74213 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2008 | 2095 | 0.010 |
Why?
|
Animals | 1 | 2010 | 168475 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 20100 | 0.010 |
Why?
|
Health Policy | 1 | 2008 | 2684 | 0.010 |
Why?
|
Signal Transduction | 1 | 2018 | 23447 | 0.010 |
Why?
|
Prospective Studies | 1 | 2018 | 54423 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 59260 | 0.010 |
Why?
|
Adolescent | 1 | 2018 | 88326 | 0.010 |
Why?
|